---
document_datetime: 2025-10-17 11:27:16
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/arava-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: arava-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.1863545
conversion_datetime: 2025-12-24 19:05:32.708789
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Arava

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number                    | Scope                                                                                                    | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                   |
|---------------------------------------|----------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000279486 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.z Change(s) in the Summary of product Characteristics, | 04/09/2025                          |                                             | SmPC and PL                      | Interstitial lung disease, as well as rare cases of pulmonary hypertension and pulmonary nodules have been reported during treatment with |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| Labelling or Package Leaflet intended to implement the outcome of a PRAC signal recommendation: implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH - Accepted To update sections 4.4 and 4.8 of the SmPC and section 4 of the PL to implement the signal recommendations on pulmonary nodule (EPITT no 20155) adopted at the 13 March 2025 PRAC meeting. In addition, the MAH took the opportunity to update the EU local representatives.   | leflunomide (see section 4.8). The risk interstitial lung disease and pulmonary hypertension can be increased in patients with a history of interstitial lung disease. Interstitial lung disease is a potentially fatal disorder, which may occur acutely during therapy. Pulmonary symptoms, such as cough and dyspnoea, may be a reason for discontinuation of the therapy and for further investigation, as appropriate. For more information, please refer to the Summary of Product Characteristics.   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|